Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
Marcin Szumowski, CEO and President of the Management Board of Molecure said “Many events of this year were crucial for further development of Molecure.
- Marcin Szumowski, CEO and President of the Management Board of Molecure said “Many events of this year were crucial for further development of Molecure.
- In June, we announced the updated strategy for 2023-2025, the implementation of which will enable us to continue building the company's value.
- Bringing two of our most advanced programs to patients opened a new and exciting chapter for Molecure.
- Molecure has signed an agreement with Simbec-Orion, a leading global Clinical Research Organisation which will conduct the clinical trial on behalf of Molecure.